Stomach

Pressure BioSciences Announces Launch of Novel, FDA Registered Immune Booster by Pending Merger Partner Cannaworx, Inc.

Thursday, May 28, 2020 - 1:10pm

The Company believes that post-launch, this product could be one of the very few, and perhaps the only, OTC (over the counter), FDA registered, hemp-containing supplements with an immune booster claim.

Key Points: 
  • The Company believes that post-launch, this product could be one of the very few, and perhaps the only, OTC (over the counter), FDA registered, hemp-containing supplements with an immune booster claim.
  • Healthy living is the primary recommended strategy to achieve this goal but this strategy can be powerfully supplemented with high quality immune boosters.
  • Immune boosters have become very popular in recent years; for example, it is estimated that the global immune booster market will exceed $25B by 2025 .
  • The active ingredient in the Cannaworx immune booster is a patented, proprietary blend of 44 amino acid fragments from pepsin.

Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules

Monday, May 18, 2020 - 5:33am

Stomach ailments, such as indigestion unrelated to overeating and stomach discomfort, prevent the enjoyment of eating on a routine basis.

Key Points: 
  • Stomach ailments, such as indigestion unrelated to overeating and stomach discomfort, prevent the enjoyment of eating on a routine basis.
  • The compounding amount of 'teprenone' was increased to 150mg / day for New Selbelle Premium from 112.5 mg / day for the conventional product.
  • In addition, New Selbelle Premium contains two natural extracts that revitalize stomach functions and digestive enzymes that help to digest fat.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com
    Media Inquiries: Public Relations Department Eisai Co., Ltd. +81-(0)3-3817-5120
    Copyright 2020 JCN Newswire .

Global Digestive Enzymes Market (2020 to 2030) - Major Players Include Garden of Life, Biotics Research Corporation & Klaire Laboratories Among Others - ResearchAndMarkets.com

Thursday, April 16, 2020 - 4:12pm

The digestive enzymes market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa.

Key Points: 
  • The digestive enzymes market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa.
  • The digestive enzymes market covered in this report is segmented by enzyme type into carbohydrates; protease; lipase; other enzyme types.
  • Digestive Enzymes Market Global Report 2020-30 from the author provides the strategists, marketers and senior management with the critical information they need to assess the global digestive enzymes market.
  • The digestive enzymes market consists of sale of digestive enzymes and related services used to ease up the digestion of food in stomach.

Cinclus Pharma Appoints Jenni Björnulfson as Chief Financial Officer

Thursday, April 16, 2020 - 8:21am

The Swedish based company Cinclus Pharma Holding AB is the 100% owner of Cinclus Pharma AG, a research-based biotech company, based in Basel, Switzerland.

Key Points: 
  • The Swedish based company Cinclus Pharma Holding AB is the 100% owner of Cinclus Pharma AG, a research-based biotech company, based in Basel, Switzerland.
  • The management team is highly experienced in the GI area (AstraZeneca, Glaxo and Novartis).
  • X842 belongs to the P-CAB class that competitively inhibits the H+, K+-ATPase in the parietal cell and thereby controls gastric acid secretion.
  • X842 is a prodrug of linaprazan, with comprehensive data from 25 Phase I studies including more than 600 subjects.

Cinclus Pharma Appoints Jenni Björnulfson as Chief Financial Officer

Thursday, April 16, 2020 - 8:18am

The Swedish based company Cinclus Pharma Holding AB is the 100% owner of Cinclus Pharma AG, a research-based biotech company, based in Basel, Switzerland.

Key Points: 
  • The Swedish based company Cinclus Pharma Holding AB is the 100% owner of Cinclus Pharma AG, a research-based biotech company, based in Basel, Switzerland.
  • The management team is highly experienced in the GI area (AstraZeneca, Glaxo and Novartis).
  • X842 belongs to the P-CAB class that competitively inhibits the H+, K+-ATPase in the parietal cell and thereby controls gastric acid secretion.
  • X842 is a prodrug of linaprazan, with comprehensive data from 25 Phase I studies including more than 600 subjects.

Debbie's Dream Foundation: Curing Stomach Cancer Announces 2019 Scholarship Essay Contest Winners

Thursday, January 30, 2020 - 1:33pm

FORT LAUDERDALE, Fla., Jan. 30, 2020 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is proud to announce the winners of the 2019 DDF Scholarship Essay Contest.

Key Points: 
  • FORT LAUDERDALE, Fla., Jan. 30, 2020 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is proud to announce the winners of the 2019 DDF Scholarship Essay Contest.
  • Nasir Thompson, 10, from Las Vegas won $100 in the elementary school division for his essay on ways to treat stomach cancer and his dreams for finding a cure.
  • Each category had a different essay prompt which asked questions regarding dreams, thoughts, and financial resources for curing stomach cancer.
  • Debbie is considered a pioneer by many for bringing awareness to the plight of stomach cancer patients worldwide, as well as to the lack of federal funding for stomach cancer research.

RedHill Biopharma Launches H. pylori Disease State Awareness Field Campaign Ahead of Talicia® Launch

Monday, January 27, 2020 - 12:00pm

The campaign aims to raise awareness among the main physicians who treat the disease, which include gastroenterologists, primary care and other healthcare providers.

Key Points: 
  • The campaign aims to raise awareness among the main physicians who treat the disease, which include gastroenterologists, primary care and other healthcare providers.
  • Our market access team has been working to establish coverage for Talicia ahead of its commercial launch, to allow more patients to benefit from this new treatment.
  • H. pylori infection is a highly prevalent Group 1 carcinogen and the strongest risk factor for peptic ulcer disease and non-cardia gastric cancer.
  • More than 27,500 Americans are diagnosed with gastric cancer each year, and more than 11,000 die from the disease annually4.

OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999

Tuesday, January 21, 2020 - 10:00am

TAIPEI, Taiwan, Jan. 21, 2020 /PRNewswire/ --OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-999 for the treatment of Gastric Cancer.

Key Points: 
  • TAIPEI, Taiwan, Jan. 21, 2020 /PRNewswire/ --OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-999 for the treatment of Gastric Cancer.
  • On December 26, 2019 OBI-999 was granted Orphan Drug Designation for Pancreatic Cancer.
  • Tillman Pearce, MD, CMO, OBI Pharma noted, "Advanced gastric cancer is an orphan disease where targeted therapies are lacking for the majority of patients.
  • Gastric cancer (GC), or stomach cancer, is a disease in which malignant cancer cells form in the lining of the stomach.

OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999

Tuesday, January 21, 2020 - 10:00am

TAIPEI, Taiwan, Jan. 21, 2020 /PRNewswire/ --OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-999 for the treatment of Gastric Cancer.

Key Points: 
  • TAIPEI, Taiwan, Jan. 21, 2020 /PRNewswire/ --OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-999 for the treatment of Gastric Cancer.
  • On December 26, 2019 OBI-999 was granted Orphan Drug Designation for Pancreatic Cancer.
  • Tillman Pearce, MD, CMO, OBI Pharma noted, "Advanced gastric cancer is an orphan disease where targeted therapies are lacking for the majority of patients.
  • Gastric cancer (GC), or stomach cancer, is a disease in which malignant cancer cells form in the lining of the stomach.

Debbie's Dream Foundation: Curing Stomach Cancer Raised Nearly $17,000 at the 4th Annual South Florida Dream Fore a Cure Golf Tournament

Tuesday, December 31, 2019 - 1:32pm

FORT LAUDERDALE, Fla., Dec. 31, 2019 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF hosted its 4thannual South Florida Dream Fore a Cure Golf Tournamenton Nov 14, 2019, at the Jacaranda Golf Club in Plantation, Florida.

Key Points: 
  • FORT LAUDERDALE, Fla., Dec. 31, 2019 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF hosted its 4thannual South Florida Dream Fore a Cure Golf Tournamenton Nov 14, 2019, at the Jacaranda Golf Club in Plantation, Florida.
  • The tournament, which raised nearly $17,000 this year, is held annually as part of DDF's mission to raise awareness and funds for stomach cancer research.
  • "This tournament is very important to me because we are here to reinforce the dream of our late founder Debbie Zelman.
  • Debbie is considered a pioneer by many for bringing awareness to the plight of stomach cancer patients worldwide and the lack of federal funding for stomach cancer research.